Literature DB >> 630211

Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type.

T A Lister, M H Cullen, M E Beard, R L Brearley, J M Whitehouse, P F Wrigley, A G Stansfeld, S B Sutcliffe, J S Malpas, D Crowther.   

Abstract

Sixty-six untreated patients with advanced non-Hodgkin's lymphoma of favourable histological type were allocated alternately to initial treatment with cyclophosphamide, vincristine, and prednisolone or with chlorambucil. The complete remission rate was higher in the group receiving combination chemotherapy, but the overall response rate was the same for both groups. The mean duration of complete remission was the same as that of good partial remission, and was the same for both treatments. The duration of remission was influenced by histological type and extent of disease at presentation, but not age. Those who responded to the initial treatment (whether with complete or with good partial remission) survived significantly longer than did non-responders. It is concluded that neither treatment is satisfactory and that new treatment programmes are needed for patients with a favourable prognosis, especially young patients with extensive disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 630211      PMCID: PMC1603216          DOI: 10.1136/bmj.1.6112.533

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  12 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Multivariate analysis of prognostic factors in the non-Hodgkin's malignant lymphomas.

Authors:  C D Bloomfield; A Goldman; F Dick; R D Brunning; B J Kennedy
Journal:  Cancer       Date:  1974-03       Impact factor: 6.860

3.  Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases.

Authors:  S E Jones; Z Fuks; M Bull; M E Kadin; R F Dorfman; H S Kaplan; S A Rosenberg; H Kim
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

4.  Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma.

Authors:  J K Luce; J F Gamble; H E Wilson; R W Monto; B L Isaacs; R L Palmer; C A Coltman; J S Hewlett; E A Gehan; E Frei
Journal:  Cancer       Date:  1971-08       Impact factor: 6.860

5.  Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.

Authors:  R I Fisher; V T DeVita; B L Johnson; R Simon; R C Young
Journal:  Am J Med       Date:  1977-08       Impact factor: 4.965

6.  Nodular lymphoma: bone marrow and blood manifestations.

Authors:  R W McKenna; C D Bloomfield; R D Brunning
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

7.  Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma.

Authors:  B Hoogstraten; A H Owens; R E Lenhard; O J Glidewell; L A Leone; K B Olson; J B Harley; S R Townsend; S Miller; C L Spurr
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

8.  Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.

Authors:  R C Young; R E Johnson; G P Canellos; B A Chabner; H D Brereton; C W Berard; V T DeVita
Journal:  Cancer Treat Rep       Date:  1977-09

9.  Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP).

Authors:  A T Skarin; D S Rosenthal; W C Moloney; E Frei
Journal:  Blood       Date:  1977-05       Impact factor: 22.113

10.  Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma.

Authors:  V Rodriguez; F Cabanillas; M A Burgess; E M McKelvey; M Valdivieso; G P Bodey; E J Freireich
Journal:  Blood       Date:  1977-03       Impact factor: 22.113

View more
  17 in total

Review 1.  Management of non-Hodgkin's lymphomas.

Authors:  P J Mounter; A L Lennard
Journal:  Postgrad Med J       Date:  1999-01       Impact factor: 2.401

2.  A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study.

Authors:  J Skillings; C Cripps; E Eisenhauer; J Pater; S Verma; D Walde
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

Review 3.  Low-grade lymphomas: new entities and treatment concepts.

Authors:  F B Hagemeister
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

Review 4.  Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients.

Authors:  Frank Heinzelmann; Hellmut Ottinger; Marianne Engelhard; Martin Soekler; Michael Bamberg; Martin Weinmann
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

5.  Cancer chemotherapy.

Authors:  R J Wrighton
Journal:  J R Soc Med       Date:  1979-01       Impact factor: 5.344

6.  The effect of chronic daily cyclophosphamide administration on established antibody responses.

Authors:  R F Gagnon; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

7.  Non-Hodgkin's lymphoma in Manitoba, 1968-77: the impact of chemotherapy.

Authors:  L Deonarine; B H Weinerman; B K MacDougall; S Kemel
Journal:  Can Med Assoc J       Date:  1982-04-01       Impact factor: 8.262

Review 8.  Economic burden of follicular non-Hodgkin's lymphoma.

Authors:  Talia Foster; Jeffrey D Miller; Mark E Boye; Mason W Russell
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma.

Authors:  T Chisesi; G Capnist; M Vespignani; G Cetto
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

10.  Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice.

Authors:  F Y Lee; P Coe; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.